Bimekizumab versus Adalimumab in Plaque Psoriasis

In this 56-week RCT, bimekizumab was noninferior and superior to adalimumab at week 1 in reducing sign/symptoms of plaque psoriasis (n=614; 86.2% vs 47.2% achieved PASI 90 response; risk difference, 39.3%; 95% CI, 30.9 to 47.7; P<0.001 for noninferiority and superiority).

Source:

New England Journal of Medicine